With two forms of influenza vaccine, BioCryst Pharma has the potential to emerge as one of the world’s top biotech companies in the fight against the swine flu. BioCryst stock has increase 450% since April 2009 reaching the best swine flu stock performed: Novavax NVAX with a 500% plus during the same period.

With a micro-injection influenza vaccine currently in phase II of development, Sanofi Adventis has the capability to develop the first swine flu vaccine. To supply the new swine flu virus at a global scale, companies like Sanofi Aventis may join efforts with other top pharmaceutical companies like AVI Biopharma (AVII), Pure Bioscience (PURE), Roche (RHHBY) and Antigenics (AGEN).